NasdaqGS - Nasdaq Real Time Price USD

Novavax, Inc. (NVAX)

3.8900

0.0000

(0.00%)

At close: April 18 at 4:00 PM EDT

3.9400

+0.05

(+1.29%)

After hours: April 18 at 7:54 PM EDT

Shah Capital nominates two highly qualified independent director candidates for Novavax

Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outd

GlobeNewswire 3 days ago

NVAX
0.00%
UPDATE 4-Novavax investor Shah Capital pushes for board shakeup

Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.

Reuters 3 days ago

NVAX
0.00%
Better Buy: Bluebird Bio Vs. Novavax

Who wins this face-to-face between two beaten-down biotechs?

Motley Fool 5 days ago

NVAX
0.00%
BLUE
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?

Is there still too much risk surrounding this business?

Motley Fool 6 days ago

NVAX
0.00%
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

Zacks 7 days ago

NVAX
0.00%
PFE
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?

The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That’s because it looks to be a rematch between President Biden and former President Trump. There’s a wildcard thrown in this time with Robert Kennedy Jr. running an independent campaign that could pull voters from both sides. The stock market went on a rollercoaster ride four years ago. A decade-long bull market was brought up short by the pandemic. The S&P 500 lost one-third of its value in a

InvestorPlace 9 days ago

VXRT
-2.75%
BLNK

NVAX
0.00%
Ex-Pharma Executive and Cousin Admit to Insider Trading of Kodak

(Bloomberg) -- A former Phlow Corp. executive and his cousin admitted to insider trading on confidential information about a pandemic-related government loan to Eastman Kodak Co. Most Read from BloombergKim Jong Un Faces Annihilation in Most Korea War ScenariosApple Explores Home Robotics as Potential ‘Next Big Thing’ After Car FizzlesTSMC Facilities to Resume Production Overnight After QuakeA Million Simulations, One Verdict for US Economy: Debt Danger AheadTrump Media’s Business Doesn’t Matter

Bloomberg 15 days ago

KODK

NVAX
0.00%
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 15 days ago

JNJ

NVAX
0.00%
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

These stocks could move in very different directions over the long run.

Motley Fool 16 days ago

TDOC
+0.30%
NVAX
0.00%
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.

PR Newswire 17 days ago

NVAX
0.00%
Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 20 days ago

NVAX
0.00%
MYGN
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

Zacks 22 days ago

MRNA
-1.39%
NVAX
0.00%
PFE
1 Beaten-Down Stock That's Still Not Worth Buying

For this biotech, a rebound seems far too unlikely.

Motley Fool last month

NVAX
0.00%
PFE
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

There’s a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they’re intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy. It’s the reason why people collect everything from baseball cards to luxury Swiss watches. Stated differently, it doesn’t take much to explain the rationale behind short-squeeze stocks to buy. On the other hand, shorting a stock represents an incredibly complex affair by

InvestorPlace last month

NVAX
0.00%
BTAI

BMEA
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

Could these biotech companies still win in the vaccine market and beyond?

Motley Fool last month

NVAX
0.00%
OCGN
The Short List: 3 Meme Stock Battlegrounds to Keep on Your Radar

Big GameStop (NYSE:GME) and AMC Entertainment (NYSE:AMC) may have lost investor focus, but these meme stocks keep interests high. Of the many indicators aiding to time the market, short interest remains the most popular. Shorting stocks, especially meme stocks, means that traders expect profits from borrowing, selling, and repurchasing them later at a discount. The percentage of float shorted gives traders a clue as to how many shares are in that transitory stage before repurchasing when they ha

InvestorPlace last month

NVAX
0.00%
HOLOW

AMC
It’s Time! 3 Failing Biotech Stocks to Sell Right Now

Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company. In other industries, this massive shift in price action isn’t nearly as prevalent. Some biotech companies are failing and won’t offer investors much in the way of returns. And they should be ditched from any watchlist bec

InvestorPlace last month

NVAX
0.00%
MRNA
-1.39%
IRWD
Exit Alert: 3 Overhyped Stocks With Weak Fundamentals

Throughout the history of financial markets, there is ample evidence of irrational investor behavior leading to euphoria. Be it the Tulip Mania of 1634 or the Housing Bubble and the subsequent financial crisis, markets tend to react on the extremes. Even today, I can spot quality stocks deeply undervalued and ignored. On the other hand, there are overhyped stocks to sell that represent companies with weak fundamentals. I must add here that investors can leverage on bullish sentiments for an indu

InvestorPlace last month

GME

NIO

NVAX
0.00%
Is Novavax a Buy Now?

The stock has dropped 98% over the past three years.

Motley Fool last month

NVAX
0.00%
Earnings Update: Novavax, Inc. (NASDAQ:NVAX) Just Reported And Analysts Are Trimming Their Forecasts

Novavax, Inc. ( NASDAQ:NVAX ) missed earnings with its latest full-year results, disappointing overly-optimistic...

Simply Wall St. last month

NVAX
0.00%

Performance Overview

Return	NVAX	S&P 500
YTD	-18.96%	+5.06%
1-Year	-58.88%	+20.71%
3-Year	-98.29%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novavax, Inc. (NVAX)

Shah Capital nominates two highly qualified independent director candidates for Novavax

UPDATE 4-Novavax investor Shah Capital pushes for board shakeup

Better Buy: Bluebird Bio Vs. Novavax

Down 60% From Its 52-Week High, Is Novavax Stock a Buy?

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?

Ex-Pharma Executive and Cousin Admit to Insider Trading of Kodak

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

1 Beaten-Down Stock That's Still Not Worth Buying

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

The Short List: 3 Meme Stock Battlegrounds to Keep on Your Radar

It’s Time! 3 Failing Biotech Stocks to Sell Right Now

Exit Alert: 3 Overhyped Stocks With Weak Fundamentals

Is Novavax a Buy Now?

Earnings Update: Novavax, Inc. (NASDAQ:NVAX) Just Reported And Analysts Are Trimming Their Forecasts

Performance Overview